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Abstract We have identified a novel human homolog of the
Drosophila dlg tumor suppressor gene, termed P-dlg, which has
been mapped at chromosome 10q23. Unlike other human dlg
homologs, P-dlg is expressed in placenta and various gland
tissues but not in brain. The P-dlg protein is localized at the
plasma membrane and cytoplasm, and it is expressed in the gland
epithelial cells in normal prostate tissue but not in prostate
cancer cell lines. Furthermore, we identified interaction between
P-dlg and p55 palmitoylated membrane protein by yeast two-
hybrid screening. These findings suggest that P-dlg forms a
complex with p55 at the plasma membrane and plays roles in
maintaining the structure of epithelial cells and transmitting
extracellular signals to the membrane and cytoskeleton, which
may negatively regulate cell proliferation.
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1. Introduction
The lethal(1)-discs large (dlg) gene was originally identi¢ed
based on its ability to act as a tumor suppressor in Drosophila
[1]. The recessive mutant of this gene leads to disruption of
normal cell-cell adhesion and neoplastic overgrowth of the
imaginal disc epithelium. The protein encoded by the dlg
gene was found to be localized in the apical-lateral membrane
of epithelium cells at the tight junction. This evidence suggests
that the wild-type dlg protein plays a role in composing and
maintaining normal epithelium structure [2].
Several vertebrate homologs of the dlg gene have been iden-
ti¢ed and characterized in recent years, and they have been
categorized into a new protein family termed MAGUK (mem-
brane-associated guanylate kinase homolog) [3]. The PSD95,
which is also known as SAP90 [4,5], is predominantly ex-
pressed in the brain, where it localizes in the postsynaptic
membrane and presynaptic axon terminals of inhibitory neu-
rons. PSD95/SAP90 binds directly to the cytoplasmic tail of
both Shaker-type voltage-gated K channels and the NR2
modulatory subunit of N-methyl-D-aspartate (NMDA)-type
glutamate receptors [6,7]. Two other dlg-related MAGUK
proteins, chapsyn 110 [8] and NE-dlg/SAP-102 [9^11], have
also been shown to interact with NMDA receptors. These
proteins contain three distinct domains: an N-terminal seg-
ment comprising one or three copies of a 80^90 amino acid
motif called PDZ (PSD-95, Dlg, ZO-1) domain, a src homol-
ogy 3 (SH3) domain, and a region with high similarity to
guanylate kinases (GUK) [12]. The PDZ domain has been
shown to be a module for interacting with various cellular
proteins. SAP90/PSD-95, hdlg-1/SAP97 [13,14] and NE-dlg/
SAP102 were found to bind to the carboxy-terminal tail of
the NMDA receptor through their PDZ domain. Further-
more, PDZ domains of NE-dlg/SAP102 and hdlg-1/SAP97
were shown to interact with APC tumor suppressor protein
[9,15]. Both the NMDA receptor and APC protein have a
threonine/serine-X-valine (T/S-X-V) motif at their carboxy-
terminal end, and this motif has been proved to speci¢cally
interact with PDZ domains. Analysis of the crystal structure
for the PDZ domain has revealed that it forms a carboxylate
binding loop utilizing its L-sheets containing the sequence
Gly-Leu-Gly-Phe (GLGF) [16] which is highly conserved in
most of the PDZ domains.
The GUK domain is homologous to the domain of the
yeast guanylate kinase which is an enzyme that catalyzes the
transfer of phosphate from ATP to GMP, forming GDP.
However, the dlg-related GUK has been found to have no
guanylate kinase activity. Recently, DAP-1, a novel protein
which interacts with GUK domains of hdlg-1 and PSD95, was
identi¢ed [17]. Thus, the GUK domain is also considered to
contribute to protein-protein interaction.
All Drosophila dlg homologs identi¢ed to date (SAP90/
PSD95, hdlg1/SAP97, and NE-dlg/SAP102) were found to
be highly expressed in neuronal cells and to be important
components for forming synaptic structure. In this study, we
have identi¢ed and characterized a novel human homolog of
Drosophila dlg, termed P-dlg, which is highly expressed in
placenta and various gland tissues, but not in brain. P-dlg
has three PDZ domains, which do not have the conserved
GLGF motif. These lines of evidence led us to hypothesize
that P-dlg has a unique function distinct from other dlg ho-
mologs. Furthermore, we have identi¢ed interaction between
P-dlg and p55 [18^21], which is a member of the MAGUK
family, using the yeast two-hybrid screening system. The bio-
logical signi¢cance of this novel dlg homolog will be dis-
cussed.
2. Materials and methods
2.1. EST database screening and PCR-based full length cDNA cloning
We searched for human homologs of the dlg gene by screening the
database of the expressed sequence tag (dbEST) at the National Cen-
ter for Biotechnology Information (NCBI). The method for PCR-
based full length cDNA cloning from EST clones was reported pre-
viously [22]. For ampli¢cation of the 5P region, the ¢rst PCR was
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performed using only primer P1 (5P-GCATCCAAGGCGAGCAG-
GTCTTT-3P) to amplify single-strand cDNA from a human fetal
brain cDNA library (Clontech, Palo Alto, CA) in a 25 Wl reaction
volume for 50 cycles. The ¢rst PCR product was used as a template in
the second run, where P2 (5P-TGCAGCCGCTGACAGCGTCT-
TTGT-3P) and T3 (5P-ATTAACCCTCACTAAAG-3P) were utilized
as primers to amplify the 5P region cDNA. For ampli¢cation of the
remaining 5P region, P3 (5P-CTTCGTGAACTCCTCAGGGCGGTA-
3P) and P5 (5P-ACTCGAAGAACCCAGGCGGGCGCT-3P) were
used for the ¢rst PCR, and P4 (5P-CACCTTCAGGCGGACGC-
CATCCCT-3P), P6 (5P-CAGTGAGTTGGACCCATGGGTGGCT-
CT-3P) and T7 (5P-AATACGACTCACTATAG-3P) were used for
the second PCR. The PCR fragments were direct-sequenced using
the same primers.
2.2. Northern blot analysis
Northern blots derived from multiple human tissues and cancer cell
lines containing 2 Wg of poly(A) RNA per lane were obtained from
Clontech. The membrane was probed with a 1.1 kbp cDNA fragment
of P-dlg that had been labeled with [K-32P]dCTP as previously de-
scribed [9].
2.3. Radiation hybrid (RH) mapping of P-dlg gene
PCR was performed to detect the P-dlg gene in the Genebridge 4
RH Screening Panel using a set of primers (S int-1: 5P-GTACA-
GAAAATCCCAGTC-3P and AS int-2: 5P-TCAAGGTATTAACT-
CGCAG-3P) which were designed based on a partial genomic se-
quence of the P-dlg gene. The primers were expected to amplify a
125 bp PCR product from human genomic DNA as a template.
PCR was carried out as previously described [9]. The PCR results
of the RH Panel were sent to the Whitehead Institute/MIT Center
for Genome Research via the internet for mapping of the genes rela-
tive to the radiation hybrid map of the human genome [23].
2.4. Production of anti-P-dlg polyclonal antibody
An antibody against a unique protein sequence in P-dlg was raised
by subcutaneous immunization of rabbits with a synthetic peptide
(KSAKHIKEKEQRDPIYLRDKVTQRH) which was coupled to
keyhole limpet hemocyanin. The antibody was a⁄nity-puri¢ed on a
column containing the peptide cross-linked to Sepharose.
2.5. Construction of the P-dlg expression plasmid
The full length ORF of the P-dlg cDNA (2577 bp) was ampli¢ed by
PCR from the VZAP human fetal brain cDNA library using rTth
DNA polymerase and a set of primers: P-top (5P-TGGACGGATC-
CATGCACGCATCACCCCCTCGCAAGG-3P) containing a BamHI
site (underlined) and the primer P-stop (5P-AGCTCTAGACTA-
GAGCGGGCAGGCTGGAAT-3P) containing a XbaI site (under-
lined). The PCR fragment was digested with BamHI and XbaI, and
ligated into a pCGN expression vector. To express HA epitope-tagged
P-dlg, the pCGN-P-dlg was transfected into COS-7 cells by the lip-
osome-mediated gene transfer method.
2.6. Western blotting
Lysates of cultured cells (HeLa S3 cell ; human cervix adenocarci-
noma cell lines, PC-3 and Du-145 cell ; human prostate tumor cell
lines) and frozen tissues were separated on an 8% polyacrylamide
gel and transferred to a nitrocellulose ¢lter with a constant current
of 140 mA for 2 h. The ¢lters were probed with 1:1000 diluted anti-
HA antibody (12CA5) and 1:500 diluted anti-P-dlg antibody using
the method previously described [9].
2.7. Immunohistochemical analysis
Frozen tissues were cut into sections 6 Wm thick and ¢xed in 10%
bu¡ered formalin for 15 min. After ¢xation, immunoperoxidase stain-
ing of the tissue sections was performed as previously described [9].
2.8. Immuno£uorescence staining and confocal laser scanning
microscopic (CLSM) analysis
HeLa S3 cells were seeded on glass-bottom culture dishes (MatTek
Corp.) and incubated for 24 h at 37‡C, then washed twice with PBS
and ¢xed in 4% PFA for 10 min followed by 0.2% Triton X-100 for
5 min. The cells were incubated with anti-P-dlg polyclonal clonal
antibody followed by treatment with FITC-conjugated secondary
antibody. After being washed with PBS, they were mounted in 50%
glycerol, and visualized with a confocal microscope (TCS 4D, Leica,
Nussloch, Germany) equipped with an argon gas laser and appropri-
ate ¢lter sets to allow the simultaneous recording of £uorescein.
2.9. Yeast two-hybrid screening
The partial P-dlg cDNA, which included three PDZ repeats and the
SH3 region, was obtained by PCR using a set of primers (5P-
TGGACGCTAGCATGCACGCATCACCCCCTCGCAAGG-3P and
5P-GACCTAGGATCCAAGGCGAGCAGGTCTTTCCCGT-3P)
containing NheI and BamHI cloning sites (underlined), respectively.
The PCR product was double digested with NheI and BamHI and
subcloned into the pBTM116HA vector as a fusion to the LexA
DNA-binding domain. The resultant plasmid, LexA-P-dlg was co-
transformed with a prey plasmid containing a human placenta
cDNA library fused to the GAL4 activation domain in the pGAD
GH vector (Clontech) by electroporation. The transformants (1U106)
were screened with streaking on selection medium (SD-Trp, -Leu and
-His) followed by L-galactosidase ¢lter assay [24]. The pGAD GH
plasmids containing the inserted cDNA were recovered from the pos-
itive clones and cotransformed with LexA-P-dlg or control baits to
con¢rm their interaction. DNA sequencing of the cDNA inserted into
the positive plasmid was performed by the dideoxynucleotide chain
termination method.
3. Results
3.1. Identi¢cation of the human gene related to Drosophila dlg
To identify the human homolog of the Drosophila dlg, we
performed sequence database searching using the Blast algo-
rithm. A tblastn search of GenBank database using the dlg
peptide sequences revealed that several EST clones have se-
quence similarity. Some of them had an identical sequence to
the PSD-95/SAP-90A gene or the p55 gene. The two potential
overlapping ESTs, H29224 and H29225, were not found to be
identical to any previously reported genes. Based on the se-
quences of these ESTs, we performed a two-step PCR to clone
the full length cDNA. We identi¢ed a 2577 bp cDNA which
contains an open reading frame encoding a polypeptide of 859
amino acids (Fig. 1).
A BLASTp search of the non-redundant protein database
revealed that the predicted amino acid sequences of the cloned
cDNA have a high similarity to a hdlg-1/SAP97 and Droso-
phila dlg with 45% and 40% identity, respectively. The P-dlg
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Fig. 1. Predicted amino acid sequence of the P-dlg (GenBank acces-
sion number U61843). On the basis of the deduced amino acid se-
quence, P-dlg contains 859 amino acids. Homologous domains and
motifs are indicated as follows: the PDZ domains (box), the SH3
domain (solid underline) and the GUK domain (dashed underline).
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has three PDZ homology domains, the SH3 domain and the
guanylate kinase homologous region (GUK). However, the
¢rst PDZ domain had weak homology compared to other
PDZ domains. The GLGF motif conserved in most of mam-
malian dlg homologs was absent in all PDZ domains of P-dlg.
3.2. Expression of P-dlg mRNA in human tissues
To determine the expression pattern of P-dlg mRNA, we
performed Northern blot analysis on various human tissues.
P-dlg transcripts were detected in thyroid, spinal cord, tra-
chea, adrenal gland, placenta and prostate. Since this gene
was highly expressed in placenta and prostate, we designated
it P-dlg. Thyroid was found to express two species (9.4 and
8.8 kbp) of P-dlg mRNA, and adrenal gland, trachea, spinal
cord, placenta and prostate expressed only one of 9.4 kbp.
Among the tumor cell lines examined, HeLa S3 cells highly
expressed P-dlg transcript (Fig. 2).
3.3. Chromosome localization of P-dlg gene
To identify the chromosome localization of the P-dlg gene,
we performed PCR mapping using the Genebridge 4 radiation
somatic cell hybrid panel. Comparison with the human chro-
mosomal content of the hybrids, as determined by the manu-
facturer and Whitehead Institute/MIT Center for Genome
Research, localized the P-dlg gene to chromosome 10q and
placed it 8.88 cR from WI-7219 (Fig. 3).
3.4. Detection of the P-dlg protein by Western blot analysis
First, Western blot analysis of COS-7 cells, which were
transiently transfected by the HA-tagged P-dlg expression
plasmid (pCGN-P-dlg), was performed using anti-HA and
anti-P-dlg antibodies. A band of about 105 kDa, which was
very similar to the calculated molecular mass of the full length
protein encoded by the P-dlg cDNA, was detected in lysates
of pCGN-P-dlg transfected COS-7 cells with both anti-HA
and anti-P-dlg antibodies (Fig. 4a). Using the P-dlg antibody,
we performed Western blot analysis to detect the endogenous
P-dlg protein in normal human prostate tissue and various
human cancer cell lines (HeLa S3, PC-3 and Du-145). The
105-kDa protein was detected in lysates from human prostate
tissues and HeLa S3 cells. However, the full length P-dlg
protein was not detected in the prostate cancer cell lines
PC-3 and Du-145 (Fig. 4b).
3.5. Immunodetection of P-dlg protein in prostate tissue and
cultured cells
The P-dlg gene was found to be expressed in various endo-
FEBS 20644 14-8-98
Fig. 4. Western blot analysis of P-dlg. a: Lysates prepared from
COS-7 cells, which were transfected with pCGN-P-dlg (lanes 2 and
4) and with pCGN (lanes 1 and 3), were detected by anti-HA anti-
body (lanes 1 and 2) and by anti-P-dlg antibody (lanes 3 and 4).
The arrow indicates the 105 kDa full length P-dlg protein. b: Ly-
sates prepared from human prostate tissue (lane 1), HeLa cells (lane
2) and two human prostate cancer cell lines, PC-3 (lane 3) and Du-
145 (lane 4) were detected by anti-P-dlg antibody. The arrow indi-
cates the 105 kDa full length P-dlg protein.
Fig. 3. Radiation hybrid mapping of the P-dlg gene. The results of
PCR using the radiation hybrid panel were sent to Whitehead Insti-
tute/MIT Center for Genome Research via WWW and placed the
P-dlg gene at 8.9 cR from WI-6610 on chromosome 10q23.
Fig. 2. Expression of P-dlg transcript in various human tissues and
cancer cell lines. Each lane contains 2 Wg of human poly(A) RNA.
Names of the tissues and cell lines are written at the top of the pan-
el.
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crine tissues including thyroid, adrenal and prostate. To de-
termine the distribution of the P-dlg protein, immunohisto-
chemical analysis using the anti-P-dlg antibody was performed
in the frozen tissue sections of normal human prostate. P-dlg
was found to be speci¢cally expressed in the cytoplasm of the
gland epithelial cells (Fig. 5a,b). We also examined localiza-
tion of P-dlg protein in HeLa S3 cells by immuno£uorescence
staining followed by confocal microscopic analysis. FITC pos-
itive staining was detected along the plasma membrane and in
cytoplasm of the cells (Fig. 5c).
3.6. Detection of an interaction between P-dlg and p55 proteins
To elucidate the function of the P-dlg protein, we per-
formed yeast two-hybrid screening for identifying proteins
that bind to the P-dlg protein. Five positive clones were ob-
tained from 1U106 transformants screened. To con¢rm the
speci¢city of the interactions, the plasmids expressing the ac-
tivation domain fusion proteins were recovered from the pos-
itive clones and cotransformed with LexA-P-dlg and control
baits. Three clones were positive in the secondary screening,
and they contained a 1.2 kbp insert whose sequence was iden-
tical to a part of the p55 gene cDNA sequence. The insert
encoded the carboxy-terminal 198 amino acids (269^466) of
the p55 protein, which contains the GUK domain (Fig. 6).
4. Discussion
We have identi¢ed and characterized the P-dlg gene, which
is a novel human homolog of the Drosophila dlg tumor sup-
pressor gene. The P-dlg transcript was highly expressed in
placenta, prostate, thyroid, trachea, and adrenal gland, but
not in brain. Additionally, immunohistochemical analysis of
normal human prostate tissue revealed that the P-dlg protein
is speci¢cally expressed in the gland epithelial cells. This ex-
pression pattern of the P-dlg gene is di¡erent from other
known human dlg homologs such as h-dlg1/SAP97 and NE-
dlg/SAP102 ; h-dlg-1/SAP97 is ubiquitously expressed in most
human normal tissues and NE-dlg/SAP102 is expressed in
brain and endocrine tissues [9].
The protein encoded by P-dlg gene has three PDZ domains,
a SH3 domain and a GUK domain, which are conserved
structures in some MAGUK family proteins. Among human
MAGUK family proteins, p55, Dlg-2 and Dlg-3 have only
one PDZ domain. In contrast, human SAP-90/PSD-95,
hdlg-1/SAP-97, NE-dlg/SAP-102 and chapsyn 110 all have
three PDZ domains and bind to the intracellular C-terminal
tails of NMDA receptor subunits. The P-dlg protein has
found to have three PDZ domains, however, the ¢rst (N-ter-
minal) PDZ has weak homology compared to the other two
PDZ domains. Furthermore, all three PDZ domains of the P-
dlg do not possess the GLGF motif, which is conserved
among most MAGUK family proteins and is necessary for
the binding to the T/S-X-V motifs in the C-terminal peptides.
InaD [25], which was identi¢ed as a molecule for clustering
proteins at the photoreceptor cells, has the sequence Phe-Leu-
Gly-Iso (FLGI) instead of the GLGF motif. Three cellular
proteins which interact with PDZ domains of InaD protein
were identi¢ed, but all these binding proteins lack the C-ter-
minal T/S-X-V motif [26]. Therefore, P-dlg, similar to InaD,
may not interact with the typical C-terminal T/S-X-V motifs.
In fact, using the yeast two-hybrid system we con¢rmed that
P-dlg does not bind to APC protein which has the C-terminal
T/S-X-V motif (data not shown). Instead, we identi¢ed an
association of P-dlg with the GUK domain of p55 by screen-
ing a prostate cDNA library employing the two-hybrid meth-
od. The C-terminal portion of p55 (289^466) has four internal
T/S-X-V motifs which are possible binding sites for the PDZ
domain of P-dlg.
p55 is a palmitoylated erythrocyte membrane protein,
which is also one of the MAGUK family proteins. p55 has
been previously shown to compose a ternary complex with the
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Fig. 6. Interaction of P-dlg with p55. a: Yeast two-hybrid assay of
HIS3 reporter construct. The yeast transformants were streaked
onto synthetic medium plates lacking tryptophan, leucine and histi-
dine. Interaction between P-dlg and p55 resulted in activation of
HIS3 reporter and enabled growth in the absence of histidine. b:
Schematic representation of p55 gene product. The insert of the
positive clone encodes the carboxy-terminal 198 amino acid frag-
ment (269^466) of the p55 protein.
Fig. 5. Immunohistochemical analysis of P-dlg using anti-P-dlg polyclonal antibody. a, b: The gland epithelial cells of the normal human pros-
tate tissue are speci¢cally stained by anti-P-dlg antibody (frozen tissue section, (a) U100, (b) U400). c: Subcellular localization of the P-dlg
protein in HeLa S3 cells. FITC positive staining is detected at the plasma membrane and the cytoplasm of HeLa S3 cells.
H. Nakamura et al./FEBS Letters 433 (1998) 63^6766
band 4.1 protein and glycophorin C at the erythroid plasma
membrane [20,21]. Genetic defects in either band 4.1 or gly-
cophorin C result in the stoichiometric reduction of p55 pro-
tein and consequently induce aberrant morphology of eryth-
rocytes and hemolysis. These lines of evidence indicate that
this complex formation is involved in the cross-bridge system
between the cytoskeleton and the plasma membrane in eryth-
rocytes. Since isoforms of p55, band 4.1, and glycophorin C
are present in many non-erythroid cells, these interactions are
considered to modulate cytoskeletal-membrane linkage of
broad cell types [19]. In fact, confocal microscopy ¢ndings
in HeLa S3 cells have shown that the P-dlg protein is also
localized at the plasma membrane and the cytoplasm. Taken
together, our ¢nding ssuggest that P-dlg and p55 form a het-
eromeric MAGUK complex at the plasma membrane and
cluster various intracellular molecules to play roles in main-
taining the structure of epithelial cells and transmitting extra-
cellular signals to the membrane and cytoskeleton.
PCR mapping using the radiation somatic cell hybrid panel
localized the P-dlg gene to chromosome 10q, 8.88 cR apart
from WI-7219. The marker WI-7219 was mapped at chromo-
some 10q23, which was reported to be the frequent loss-of-
heterozygosity region in prostate and endometrial tumors.
Although P-dlg protein is abundantly expressed in normal
prostate tissue, human prostate tumor cells (PC-3 and Du-
145 cells) do not express P-dlg protein. These ¢ndings imply
that the P-dlg gene is one of the candidate tumor suppressor
genes in chromosome 10q23 and that a loss of function of the
P-dlg gene may lead to the development of prostate tumor.
Since P-dlg transcript was detected in the human prostate
cancer cell lines examined (data not shown), detailed mutation
analyses of the P-dlg gene will be required for an assessment
of the involvement of P-dlg in the development of the tumors.
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